Reuters logo
BRIEF-Can-Fite’s Phase II NAFLD/NASH trial with Namodenoson to begin patient enrollment after clinical investigator meeting
July 17, 2017 / 11:35 AM / 2 months ago

BRIEF-Can-Fite’s Phase II NAFLD/NASH trial with Namodenoson to begin patient enrollment after clinical investigator meeting

July 17 (Reuters) - Can Fite Biopharma Ltd

* Can-Fite’s Phase II NAFLD/NASH trial with Namodenoson set to commence patient enrollment following conclusion of successful clinical investigator meeting

* Can-Fite BioPharma Ltd - ‍anticipate patient enrollment for Phase II NAFLD/NASH trial with Namodenoson to commence this quarter​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below